94,443 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Bought by NEXTBio Capital Management LP

NEXTBio Capital Management LP acquired a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 94,443 shares of the company’s stock, valued at approximately $6,569,000. Structure Therapeutics comprises approximately 3.9% of NEXTBio Capital Management LP’s holdings, making the stock its 10th biggest position.

Several other institutional investors and hedge funds have also modified their holdings of GPCR. Geode Capital Management LLC lifted its position in shares of Structure Therapeutics by 18.5% during the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after buying an additional 8,444 shares during the last quarter. Invesco Ltd. lifted its position in shares of Structure Therapeutics by 7.6% during the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after buying an additional 30,162 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Structure Therapeutics by 474.9% during the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock worth $3,651,000 after buying an additional 145,434 shares during the last quarter. Jump Financial LLC lifted its position in shares of Structure Therapeutics by 105.9% during the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock worth $1,311,000 after buying an additional 32,524 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in Structure Therapeutics in the 2nd quarter worth about $3,480,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Trading Down 0.9%

Structure Therapeutics stock opened at $42.93 on Friday. The company has a market capitalization of $3.05 billion, a PE ratio of -49.34 and a beta of -1.35. The stock has a 50-day moving average price of $43.64 and a two-hundred day moving average price of $57.18. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. As a group, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on GPCR. Citizens Jmp dropped their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Finally, Wolfe Research began coverage on Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $106.75.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.